1-11 of 11
Lee M. Krug
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

Marjorie G. Zauderer, Anne S. Tsao, Tao Dao, Katherine Panageas, W. Victoria Lai, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, Michelle S. Ginsberg, Daniel Gomez, David Rice, Reza Mehran, David A. Scheinberg, Lee M. Krug
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7483–7489.
https://doi.org/10.1158/1078-0432.CCR-17-2169
Published: 14 December 2017
View article titled, A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Open the PDF for A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie G. Zauderer, Martijn P. Lolkema, Doris Apt, Ru-Fang Yeh, Jill O. Fredrickson, Jill M. Spoerke, Hartmut Koeppen, Joseph A. Ware, Jennifer O. Lauchle, Howard A. Burris, 3rd, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2874–2884.
https://doi.org/10.1158/1078-0432.CCR-15-2225
Published: 14 June 2016
View article titled, Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment

Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, Filippo Giancotti
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4485–4490.
https://doi.org/10.1158/1078-0432.CCR-11-2375
Published: 30 August 2012
View article titled, New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Open the PDF for New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment in another window
Journal Articles

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, Dyana K. Sumner, William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Timothy A. Chan, Naiyer A. Rizvi, Christopher G. Azzoli, Gregory J. Riely, Mark G. Kris, Lee M. Krug
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1138–1145.
https://doi.org/10.1158/1078-0432.CCR-11-2059
Published: 14 February 2012
View article titled, Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
Open the PDF for Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker in another window
Includes: Supplementary data
Journal Articles

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

Naiyer A. Rizvi, Valerie Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit Bains, Robert Downey, Raja Flores, Bernard Park, Bhuvanesh Singh, Maureen Zakowski, Robert T. Heelan, Ronglai Shen, Mark G. Kris
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3500–3506.
https://doi.org/10.1158/1078-0432.CCR-10-2102
Published: 15 May 2011
View article titled, Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene
Open the PDF for Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene in another window
Journal Articles

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Yelena Y. Janjigian, Christopher G. Azzoli, Lee M. Krug, Leanne K. Pereira, Naiyer A. Rizvi, M Catherine Pietanza, Mark G. Kris, Michelle S. Ginsberg, William Pao, Vincent A. Miller, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2521–2527.
https://doi.org/10.1158/1078-0432.CCR-10-2662
Published: 14 April 2011
View article titled, Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Open the PDF for Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib in another window
Journal Articles

A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors

Christopher G. Azzoli, Lee M. Krug, Jorge Gomez, Vincent A. Miller, Mark G. Kris, Michelle S. Ginsberg, Roxanne Henry, Jessica Jones, Leslie Tyson, Megan Dunne, Barbara Pizzo, Amy Farmer, Ennapadam Venkatraman, Robert Steffen, F.M. Sirotnak
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2692–2698.
https://doi.org/10.1158/1078-0432.CCR-06-1754
Published: 01 May 2007
View article titled, A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors in another window
Journal Articles

Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin

Lee M. Krug, Govind Ragupathi, Chandra Hood, Mark G. Kris, Vincent A. Miller, Jennifer R. Allen, Stacy J. Keding, Samuel J. Danishefsky, Jorge Gomez, Leslie Tyson, Barbara Pizzo, Valerie Baez, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6094–6100.
https://doi.org/10.1158/1078-0432.CCR-04-0482
Published: 24 September 2004
View article titled, Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin
Open the PDF for Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin in another window
Journal Articles

Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin

Lee M. Krug, Govind Ragupathi, Kenneth K. Ng, Chandra Hood, Harold J. Jennings, Zhongwu Guo, Mark G. Kris, Vincent Miller, Barbara Pizzo, Leslie Tyson, Valerie Baez, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 916–923.
https://doi.org/10.1158/1078-0432.CCR-03-0101
Published: 10 February 2004
View article titled, Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or <em>N</em>-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin
Open the PDF for Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or <em>N</em>-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin in another window
Journal Articles

10-Propargyl-10-deazaaminopterin: An Antifolate with Activity in Patients with Previously Treated Non-Small Cell Lung Cancer

Lee M. Krug, Christopher G. Azzoli, Mark G. Kris, Vincent A. Miller, Nushmia Z. Khokhar, William Tong, Michelle S. Ginsberg, Ennapadam Venkatraman, Leslie Tyson, Barbara Pizzo, Valerie Baez, Kenneth K. Ng, F. M. Sirotnak
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2072–2078.
Published: 01 June 2003
View article titled, 10-Propargyl-10-deazaaminopterin: <subtitle>An Antifolate with Activity in Patients with Previously Treated Non-Small Cell Lung Cancer</subtitle>
Open the PDF for 10-Propargyl-10-deazaaminopterin: <subtitle>An Antifolate with Activity in Patients with Previously Treated Non-Small Cell Lung Cancer</subtitle> in another window
Journal Articles

Phase I and Pharmacokinetic Study of 10-Propargyl-10-deazaaminopterin, a New Antifolate

Lee M. Krug, Kenneth K. Ng, Mark G. Kris, Vincent A. Miller, William Tong, Robert T. Heelan, Larry Leon, Denis Leung, Jean Kelly, F. M. Sirotnak
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3493–3498.
Published: 01 September 2000
View article titled, Phase I and Pharmacokinetic Study of 10-Propargyl-10-deazaaminopterin, a New Antifolate
Open the PDF for Phase I and Pharmacokinetic Study of 10-Propargyl-10-deazaaminopterin, a New Antifolate in another window